SR ONE CAPITAL MANAGEMENT, LP — 13F Holdings & Portfolio
CIK 1910264 · latest 13F-HR filed 2026-05-14
SR ONE CAPITAL MANAGEMENT, LP manages $915.4M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ACLX (29.43%), MANE (16.57%), ZBIO (10.76%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 7, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$915.4M
Long-equity book
14
Distinct positions
2026-03-31
Filed 2026-05-14
+1 / −0 / ↑7 / ↓6
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Arcellx, Inc.$116.4M +76.1%
- Alumis Inc.$24.0M +125.7%
- ORIC Pharmaceuticals, Inc.$20.7M +54.9%
- Design Therapeutics, Inc.$8.2M +13.4%
- Oruka Therapeutics, Inc$8.1M +61.8%
Top Trims
- Zenas BioPharma, Inc-$84.4M -46.2%
- ARS Pharmaceuticals, Inc.-$14.5M -31.1%
- Mineralys Therapeutics Inc.-$14.4M -25.4%
- CRISPR Therapeutics AG-$9.9M -9.3%
- enGene Holdings Inc.-$1.7M -24.6%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 03940C100 | $269.4M | 29.43% | 2,346,630 | SH |
| 2 | Veradermics, Inc. | MANE | 922967104 | $151.7M | 16.57% | 2,401,868 | SH |
| 3 | Zenas BioPharma, Inc | ZBIO | 98937L105 | $98.5M | 10.76% | 5,037,854 | SH |
| 4 | CRISPR Therapeutics AG | CRSP | H17182108 | $97.0M | 10.59% | 2,038,763 | SH |
| 5 | Design Therapeutics, Inc. | DSGN | 25056L103 | $69.4M | 7.59% | 6,526,476 | SH |
| 6 | ORIC Pharmaceuticals, Inc. | ORIC | 68622P109 | $58.5M | 6.39% | 4,514,929 | SH |
| 7 | Alumis Inc. | ALMS | 022307102 | $43.2M | 4.72% | 1,959,896 | SH |
| 8 | Mineralys Therapeutics Inc. | MLYS | 603170101 | $42.4M | 4.63% | 1,563,966 | SH |
| 9 | ARS Pharmaceuticals, Inc. | SPRY | 82835W108 | $32.2M | 3.52% | 4,012,903 | SH |
| 10 | Oruka Therapeutics, Inc | ORKA | 687604108 | $21.1M | 2.31% | 430,330 | SH |
| 11 | Oculis Holding AG | OCS | H5870P102 | $17.0M | 1.86% | 641,022 | SH |
| 12 | Nkarta, Inc. | NKTX | 65487U108 | $7.0M | 0.77% | 3,333,333 | SH |
| 13 | enGene Holdings Inc. | ENGNW | 29286M105 | $5.1M | 0.56% | 747,750 | SH |
| 14 | Ultragenyx Pharmaceutical Inc. | RARE | 90400D108 | $2.9M | 0.32% | 137,753 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $915.4M | 14 | 0001193125-26-224136 |
| 2025-12-31 | 2026-02-12 | $706.4M | 13 | 0001193125-26-048808 |
| 2025-09-30 | 2025-11-12 | $691.4M | 12 | 0001193125-25-277769 |